Cost-Effectiveness Analysis of Teneligliptin V/S Glimepiride as an Add-on to Metformin in Type 2 Diabetes Mellitus
Abstract
Background: Diabetes is a major lifestyle disorder. Proper glycemic control is needed to prevent the development of patients with Type 2 diabetes. Glimepiride is a second- generation sulphonyl urea with better safety and efficacy, and is commonly prescribed compared to other drugs of that class. teneligliptin is a relatively newer dipeptidyl peptidase inhibitor with proven clinical efficacy with metformin. A more cost-effective treatment option is important in the case of people with a poor economic background for better adherence and thereby preventing complications and economic burden.
Methods: A prospective observation study was conducted in a tertiary care hospital to assess and compare the cost-effectiveness of glimepiride 1mg and teneligliptin 20 mg when added to metformin 500 mg. a total of 112 patients were selected as per the inclusion criteria, 56 of them allocated to group A are taking glimepiride 1 mg and metformin 500 mg once daily. Group B patients are those who are on teneligliptin 20 mg and metformin 500 mg once daily. Fasting blood glucose and post-prandial blood glucose of each patient in both groups were recorded as baseline.
Results: The average cost-effectiveness ratio is calculated using the average cost of therapy for 4 months and the average reduction in effectiveness for 4 months. In this study, cost data included direct costs of purchasing the drugs. cost-effectiveness analysis revealed that glimepiride metformin combination showed better effectiveness in terms of both FBG and PPBG reduction. Teneligliptin and metformin therapy have shown satisfactory reduction in blood glucose levels, but it is much costlierCompared to teneligliptin, glimepiride is a better choice as an add-on drug in the absence of any contraindication in patients who are highly concerned about cost, to reduce economic burden, and to improve adherence, when used as an initial combination in patients with Type 2 diabetes mellitus.
References
Gavina C, Carvalho DS, Dias DM, Bernardo F, Martinho H, Couceiro J, Santos-Araújo C, Dinis Oliveira RJ, Taveira-Gomes T. Premature Mortality in Type 2 Diabetes Mellitus Associated with Heart Failure and Chronic Kidney Disease: 20 Years of Real-World Data. Journal of Clinical Medicine. 2022; 11(8):2131. https://doi.org/10.3390/jcm11082131
Haghighatpanah M, Nejad ASM, Haghighatpanah M, Thunga G, Mallayasamy S. Factors that Correlate with Poor Glycemic Control in Type 2 Diabetes Mellitus Patients with Complications. Osong Public Health Res Perspect. 2018 Aug;9(4):167-174. doi: 10.24171/j.phrp.2018.9.4.05. PMID: 30159222; PMCID: PMC6110332.
Simeon I Taylor et al Pharmacological Treatent of Hyperglycemia in Type 2 diabetes The Journal of Clinical investigations 2021 Jan19;131(2): e142243.doi:10.1172/JCI142243.
Bernard Zinman, Initial Combination Therapy for Type 2 Diabetes Mellitus: Is It Ready for Prime Time? The American Journal of Medicine,Volume 124, Issue 1, Supplement, 2011,Pages S19 S34,ISSN 0002 9343,https://doi.org/10.1016/j.amjmed.2010.1 1.003.
(https://www.sciencedirect.com/science/article /pii/S0002934310009174)
Hermann LS. Metformin: a review of its pharmacological properties and therapeutic use. Diabetes & Metabolism. 1979 Sep;5(3):233-245. PMID: 387488.
Deacon CF, Lebovitz HE. Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas. Diabetes Obes Metab. 2016 Apr;18(4):333-47. doi: 10.1111/dom.12610. Epub 2016 Jan 8. PMID: 26597596.
Sahay RK, Mittal V, Gopal GR, Kota S, Goyal G, Abhyankar M, Revenkar S. Glimepiride and Metformin Combinations in Diabetes Comorbidities and Complications: Real-World Evidence. Cureus. 2020 Sep 28;12(9):e10700. doi: 10.7759/cureus.10700. PMID: 33133865; PMCID: PMC7594657.
Kanimozhi M, Bisht M, Ravikant, Bandyopadhyay A, Naithani M, Handu S. Pleiotropic effect of teneligliptin versus glimepiride add-on therapy on hs-CRP and cardiorenal parameters in Indian type 2 diabetes patients: An open-labeled randomized controlled trial. Perspect Clin Res. 2025 Jan-Mar;16(1):14-22. doi: 10.4103/picr.picr_265_23. Epub 2024 Jul 10. PMID: 39867519; PMCID: PMC11759232.
Bommer C, Heesemann E, Sagalova V, Manne Goehler J, Atun R, Bärnighausen T, Vollmer S. The Journal of Pharmacoeconomics & Pharmaceutical Management global economic burden of diabetes in adults aged 20-79 years: a cost-of-illness study. Lancet Diabetes Endocrinol. 2017 Jun;5(6):423-430. doi: 10.1016/S2213-8587(17)30097-9. Epub 2017 Apr 26. PMID: 28456416.
Pradeepa R, Mohan V. Epidemiology of type 2 diabetes in India. Indian J Ophthalmol. 2021 Nov;69(11):2932-2938. doi: 10.4103/ijo.IJO_1627_21. PMID: 34708726; PMCID: PMC8725109.
Rasheed, Razia Abdul; Venkatraman, G.1; Vijayalakshmi, S.; Raja, T. A. R.; Senthil, G.; Renugadevi, P.. Effect of glimepiride versus teneligliptin in combination with metformin in type 2 diabetes mellitus patients. Indian Journal of Pharmacology 56(5):p 317-321, Sep–Oct 2024. | DOI: 10.4103/ijp.ijp_107_24
Tandon T, Dubey AK, Srivastava S, Manocha S, Arora E, Hasan N. A pharmacoeconomic analysis to compare cost-effectiveness of metformin plus teneligliptin with metformin plus glimepiride in patients of type-2 diabetes mellitus. J Family Med Prim Care. 2019 Mar;8(3):955-959. doi: 10.4103/jfmpc.jfmpc_22_19. PMID: 31041232; PMCID: PMC6482796.
Nishanth T, Maheshwari CU, Lakshmi RS, Sri D, Goud P, Tabassum K, Nadeem MT. A study to compare efficacy of metformin-glimepiride versus metformin-teneligliptin in type II diabetic patients. Int J Pharm Sci Res. 2018 Dec 1;9(12):5258-64.
Anjoom M, Dutta S, Beg MA, Varma A, Bawa S, Kant R. Comparative evaluation of combination of metformin and glimepiride with that of metformin and sitagliptin in type 2 diabetes mellitus with respect to glycemic targets. Int J Med Sci Public Health. 2015 Apr 1;4(4):476-80.
John NN, Arjun VJ, David D, Doddayya H. Pharmacoeconomic Evaluation of Antidiabetic Agents-Metformin Plus Teneligliptin Versus Metformin Plus Glimepiride-A Prospective Study.
Gautam A, Singh SV, Gupta A, Sharma A, Gupta S, Pursnani N, Agrawal P. Comparison of efficacy between canagliflozin and teneligliptin as add on therapy to metformin and glimepiride on plasma glucose levels along with blood pressure and lipid levels in patients with type 2 diabetes mellitus. Journal Of Diabetology. 2023 Jul 1;14(3):157-60.
